{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:05:53Z","timestamp":1791525953631,"version":"4.3.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Identification of plasma cells into abnormal (APC) and normal (NPC) compartments is of utmost importance in flow cytometric (FC) analysis of multiple myeloma (MM) and related plasma cell dyscrasias for diagnosis, prognosis, and follow-up. No single phenotypic marker is sufficient to distinguish NPC from APC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      43 newly diagnosed cases of MM and 13 controls were included in the study. Bone marrow (BM) samples from the 2\n                      <jats:sup>nd<\/jats:sup>\n                      pass were processed on the same day with antibodies against CD38, CD138, CD19, CD81, CD45, CD117, CD200, CD56, cytoKappa, and cytoLambda in a 4-color experiment with CD38 and CD138 as gating antibodies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Mean APC% in cases was 96.5%. The expected Immunophenotype (IP) of APC which is CD19-\/56+\/45-\/81-\/117+\/200+ was found in only 13\/43 MM cases. In 30\/43 cases, APC revealed deviation from expected IP either for single or a combination of markers. Sensitivity for APC detection was highest for CD19 (95.2%) followed by CD56 (90.4%) and CD81 (83.7%). Specificity was highest for CD19 (100%), CD56 (100%), and CD81 (100%) followed by CD117 (92.3%). Combination of markers with maximum sensitivity to detect APC (97.6%) was CD81- or CD19- and CD200+ or CD56+ (two markers); and for NPC (92.3%) was CD81+ and CD19+ and CD56- (three markers).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Plasma cell IP can be highly variable with multiple minor subpopulations in both cases and normal controls. CD 19 and CD56 are highly informative markers for a 4-color experiment. Assessment of multiple markers in an 8\u201310 color experiment is more informative but the lack of advanced flow cytometers should not limit the use of FC in a 4-color approach. Our results emphasize that even basic equipment with limited fluorochrome can provide meaningful information if used appropriately.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_505_21","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T02:34:33Z","timestamp":1717036473000},"page":"295-300","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients"],"prefix":"10.4103","volume":"66","author":[{"given":"Namrata Punit","family":"Awasthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bajpayee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradyumn","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuzhat","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20240829","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: Results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"R2-11-20240829","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.leukres.2013.12.007","article-title":"Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases","volume":"38","author":"Tembhare","year":"2014","journal-title":"Leuk Res"},{"key":"R3-11-20240829","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cyto.b.20512","article-title":"Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders","volume":"78","author":"Paiva","year":"2010","journal-title":"Cytometry Part B Clin Cytom"},{"key":"R4-11-20240829","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.beha.2010.09.002","article-title":"Immunophenotyping in multiple myeloma and related plasma cell disorders","volume":"23","author":"Kumar","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"R5-11-20240829","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","article-title":"Phenotypic difference of normal plasma cells from mature myeloma cells","volume":"81","author":"Harada","year":"1993","journal-title":"Blood"},{"key":"R6-11-20240829","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/cyto.b.20601","article-title":"Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors","volume":"80","author":"Peceliunas","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"key":"R7-11-20240829","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R8-11-20240829","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1309\/AJCP1GYI7EHQYUYK","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Gupta","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"R9-11-20240829","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/cyto.b.21218","article-title":"Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of \u201cnormal\u201d residual plasma cell analysis","volume":"88","author":"Pojero","year":"2015","journal-title":"Cytometry B Clin Cytom"},{"key":"R10-11-20240829","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1038\/bcj.2017.90","article-title":"Current applications of multiparameter flow cytometry in plasma cell disorders","volume":"7","author":"Jel\u00ednek","year":"2017","journal-title":"Blood Cancer J"},{"key":"R11-11-20240829","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2141.2006.06068.x","article-title":"Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration","volume":"133","author":"Nadav","year":"2006","journal-title":"Br J Haematol"},{"key":"R12-11-20240829","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J Clin Oncol"},{"key":"R13-11-20240829","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cyto.b.21276","article-title":"Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma","volume":"90","author":"Oldaker","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"R14-11-20240829","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"R15-11-20240829","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1182\/blood-2019-131730","article-title":"Immunophenotype drift of residual plasma cells indicates therapeutic response and prognosis in multiple myeloma","volume":"134","author":"Du","year":"2019","journal-title":"Blood"},{"key":"R16-11-20240829","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1046\/j.1365-2141.1998.00623.x","article-title":"The myeloma cell antigen syndecan- 1 is lost by apoptotic myeloma cells","volume":"100","author":"Jourdan","year":"1998","journal-title":"Br J Haematol"},{"key":"R17-11-20240829","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/eji.201646632","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies","volume":"47","author":"Cossarizza","year":"2017","journal-title":"Eur J Immunol"},{"key":"R18-11-20240829","first-page":"79","article-title":"The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders","volume":"27","author":"Treon","year":"2000","journal-title":"Semin Oncol"},{"key":"R19-11-20240829","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/jclinpath-2012-200881","article-title":"Immunophenotypic heterogeneity of normal plasma cells: Comparison with minimal residual plasma cell myeloma","volume":"65","author":"Liu","year":"2012","journal-title":"J Clin Pathol"},{"key":"R20-11-20240829","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3324\/haematol.12171","article-title":"Expression of c-Kit isoforms in multiple myeloma: Differences in signaling and drug sensitivity","volume":"93","author":"Montero","year":"2008","journal-title":"Haematologica"},{"key":"R21-11-20240829","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2141.1991.tb08050.x","article-title":"Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells","volume":"79","author":"Van Riet","year":"1991","journal-title":"Br J Haematol"},{"key":"R22-11-20240829","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1046\/j.1365-2141.1999.01134.x","article-title":"Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression","volume":"104","author":"Raswstron","year":"1999","journal-title":"Br J Haematol"},{"key":"R23-11-20240829","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fimmu.2014.00137","article-title":"Immunophenotype of normal and myelomatous plasma-cell subsets","volume":"5","author":"Robillard","year":"2014","journal-title":"Front Immunol"},{"key":"R24-11-20240829","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1309\/AJCP8TF3WUIWLZHU","article-title":"Immunophenotypic stability of CD200 expression in plasma cell myeloma","volume":"137","author":"Olteanu","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"R25-11-20240829","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","article-title":"CD200 is a new prognostic factor in multiple myeloma","volume":"108","author":"Moreaux","year":"2006","journal-title":"Blood"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_505_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:32:53Z","timestamp":1787067173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_505_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_505_21","relation":{},"ISSN":["0377-4929"],"issn-type":[{"value":"0377-4929","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}